Cobimetinib is a MEK kinase inhibitor, used for treating melanoma with BRAF V600E or V600K mutations.54 SHP099 is an allosteric inhibitor that inhibits SHP2’s activity by binding to multiple structural domain interfaces of SHP2. The gene discussed is BRAF; the disease is melanoma.